Statins Reduce COVID-19 Severity by Removing Cholesterol Used by SARS-CoV-2 to Infect Cells
By HospiMedica International staff writers Posted on 25 Sep 2020 |

Image: SARS-CoV-2 infection (green, left) is inhibited by 25HC treatment (right) (Photo courtesy of UC San Diego Health)
Researchers analyzing anonymized patient medical records have discovered that cholesterol-lowering statins reduced risk of severe COVID-19 infection, while lab experiments have uncovered a cellular mechanism that helps explain why.
Researchers from the UC San Diego Health (San Diego, CA, USA) have reported that statins - widely used cholesterol-lowering medications - are associated with reduced risk of developing severe COVID-19 disease, as well as faster recovery times. A second research team at UC San Diego School of Medicine (San Diego, CA, USA) has uncovered evidence that helps explains why: In short, removing cholesterol from cell membranes prevents the coronavirus from getting in.
The team retrospectively analyzed the electronic medical records of 170 patients with COVID-19 and 5,281 COVID-negative control patients hospitalized at UC San Diego Health between February and June 2020. They collected anonymized data that included the patients’ disease severity, length of hospital stay, outcome, and use of statins, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) within 30 days prior to hospital admission. Among the patients with COVID-19, 27% were actively taking statins on admission, while 21% were on an ACE inhibitor and 12% on an ARB. The median length of hospital stay was 9.7 days for patients with COVID-19. The researchers found that statin use prior to hospital admission for COVID-19 was associated with a more than 50% reduction in the risk of developing severe COVID-19, as compared to those with COVID-19 but not taking statins. Patients with COVID-19 who were taking statins prior to hospitalization also recovered faster than those not taking the cholesterol-lowering medication.
Another team from the UC San Diego School of Medicine was studying which genes are switched “on” in human lung cells in response to SARS-CoV-2 infection. They found a gene called CH25H which encodes an enzyme that modifies cholesterol. CH25H’s enzymatic activity produces a modified form of cholesterol called 25-hydroxycholesterol (25HC). In turn, 25HC activates another enzyme called ACAT, found inside cells in the endoplasmic reticulum. ACAT then depletes accessible cholesterol on the cell’s membrane. This normally occurring process gets kicked into high gear during some viral infections. The team quickly got to work examining 25HC in the context of SARS-CoV-2 from several angles. They explored what happens to human lung cells in the lab with and without 25HC treatment when they are exposed to first a noninfectious virus that carries the SARS-CoV-2 spike protein (its key to cell entry) or to live SARS-CoV-2 virus itself. No matter which way they came at it, added 25HC inhibited the ability of the virus to enter cells, blocking infection almost completely.
While SARS-CoV-2 uses the ACE2 receptor to initially dock on a cell, the study by the UC San Diego School of Medicine suggests that the virus also needs cholesterol (normally found in cell membranes) in order to fuse with and enter the cell. 25HC takes away a lot of that membrane cholesterol, preventing viral entry. In a similar way, statins are likely beneficial in preventing or reducing the severity of SARS-CoV-2 infection because, while intended to remove cholesterol from blood vessels, they are also removing cholesterol from cell membranes. As a result, the coronavirus cannot get in. The researchers believe that if 25HC can be developed into a therapeutic, then it might work even better as an antiviral than statins as it works specifically on cholesterol in cell membranes, rather than cholesterol throughout the body.
“We found that statins are not only safe but potentially protective against a severe COVID-19 infection,” said Lori Daniels, MD, professor and director of the Cardiovascular Intensive Care Unit at UC San Diego Health. “Statins specifically may inhibit SARS-CoV-2 infection through its known anti-inflammatory effects and binding capabilities as that could potentially stop progression of the virus.”
“I tell my patients who are on statins, ACE inhibitors or other ARBs to keep taking them,” added Daniels. “Fears of COVID-19 should not be a reason to stop, if anything our research findings should be incentive to continue with their medication.”
Related Links:
UC San Diego Health
UC San Diego School of Medicine
Researchers from the UC San Diego Health (San Diego, CA, USA) have reported that statins - widely used cholesterol-lowering medications - are associated with reduced risk of developing severe COVID-19 disease, as well as faster recovery times. A second research team at UC San Diego School of Medicine (San Diego, CA, USA) has uncovered evidence that helps explains why: In short, removing cholesterol from cell membranes prevents the coronavirus from getting in.
The team retrospectively analyzed the electronic medical records of 170 patients with COVID-19 and 5,281 COVID-negative control patients hospitalized at UC San Diego Health between February and June 2020. They collected anonymized data that included the patients’ disease severity, length of hospital stay, outcome, and use of statins, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) within 30 days prior to hospital admission. Among the patients with COVID-19, 27% were actively taking statins on admission, while 21% were on an ACE inhibitor and 12% on an ARB. The median length of hospital stay was 9.7 days for patients with COVID-19. The researchers found that statin use prior to hospital admission for COVID-19 was associated with a more than 50% reduction in the risk of developing severe COVID-19, as compared to those with COVID-19 but not taking statins. Patients with COVID-19 who were taking statins prior to hospitalization also recovered faster than those not taking the cholesterol-lowering medication.
Another team from the UC San Diego School of Medicine was studying which genes are switched “on” in human lung cells in response to SARS-CoV-2 infection. They found a gene called CH25H which encodes an enzyme that modifies cholesterol. CH25H’s enzymatic activity produces a modified form of cholesterol called 25-hydroxycholesterol (25HC). In turn, 25HC activates another enzyme called ACAT, found inside cells in the endoplasmic reticulum. ACAT then depletes accessible cholesterol on the cell’s membrane. This normally occurring process gets kicked into high gear during some viral infections. The team quickly got to work examining 25HC in the context of SARS-CoV-2 from several angles. They explored what happens to human lung cells in the lab with and without 25HC treatment when they are exposed to first a noninfectious virus that carries the SARS-CoV-2 spike protein (its key to cell entry) or to live SARS-CoV-2 virus itself. No matter which way they came at it, added 25HC inhibited the ability of the virus to enter cells, blocking infection almost completely.
While SARS-CoV-2 uses the ACE2 receptor to initially dock on a cell, the study by the UC San Diego School of Medicine suggests that the virus also needs cholesterol (normally found in cell membranes) in order to fuse with and enter the cell. 25HC takes away a lot of that membrane cholesterol, preventing viral entry. In a similar way, statins are likely beneficial in preventing or reducing the severity of SARS-CoV-2 infection because, while intended to remove cholesterol from blood vessels, they are also removing cholesterol from cell membranes. As a result, the coronavirus cannot get in. The researchers believe that if 25HC can be developed into a therapeutic, then it might work even better as an antiviral than statins as it works specifically on cholesterol in cell membranes, rather than cholesterol throughout the body.
“We found that statins are not only safe but potentially protective against a severe COVID-19 infection,” said Lori Daniels, MD, professor and director of the Cardiovascular Intensive Care Unit at UC San Diego Health. “Statins specifically may inhibit SARS-CoV-2 infection through its known anti-inflammatory effects and binding capabilities as that could potentially stop progression of the virus.”
“I tell my patients who are on statins, ACE inhibitors or other ARBs to keep taking them,” added Daniels. “Fears of COVID-19 should not be a reason to stop, if anything our research findings should be incentive to continue with their medication.”
Related Links:
UC San Diego Health
UC San Diego School of Medicine
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
Innovative Risk Score Predicts Heart Attack or Stroke in Kidney Transplant Candidates
Heart researchers have utilized an innovative risk assessment score to accurately predict whether patients being evaluated for kidney transplants are at risk for future major cardiac events, such as a... Read more
AI Algorithm Detects Early-Stage Metabolic-Associated Steatotic Liver Disease Using EHRs
Liver disease, which is treatable when detected early, often goes unnoticed until it reaches advanced stages. Metabolic-associated steatotic liver disease (MASLD), the most prevalent form of liver disease,... Read moreCritical Care
view channel
Novel Coating Significantly Extends Longevity of Implantable Biosensors
Wearable and implantable biosensors capable of accurately detecting biological molecules in a non-invasive or minimally invasive way offer enormous potential for monitoring patients’ health and their responses... Read more
Nanogel-Based Drug Delivery Technology to Improve UTI Treatment
Urinary tract infections (UTIs) are not only widespread and costly but also highly debilitating, significantly impacting the quality of life for those affected. The antibiotics commonly used to treat UTIs... Read more
New IV Pole Improves Safety and Ease of Administering IV Medications at Hospital Bedside
Preventable medication errors affect around 500,000 hospitalized patients in the U.S. every year. A significant portion of these errors occur with intravenous (IV) smart pumps, which require a precise... Read moreSurgical Techniques
view channel
Easy-To-Apply Gel Could Prevent Formation of Post-Surgical Abdominal Adhesions
Surgical adhesions are a frequent and often life-threatening complication following open or laparoscopic abdominal surgery. These adhesions develop in the weeks following surgery as the body heals.... Read more
Groundbreaking Leadless Pacemaker to Prevent Invasive Surgeries for Children
Leadless pacemakers marked a significant advancement in cardiac care, primarily because traditional pacemakers are dependent on leads, which are prone to breakage over time. Currently, two FDA-approved... Read morePatient Care
view channel
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more
Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more
Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
A groundbreaking innovation enables hospitals to significantly improve instrument processing time and throughput in operating rooms (ORs) and sterile processing departments. Turbett Surgical, Inc.... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Smartwatches Could Detect Congestive Heart Failure
Diagnosing congestive heart failure (CHF) typically requires expensive and time-consuming imaging techniques like echocardiography, also known as cardiac ultrasound. Previously, detecting CHF by analyzing... Read morePoint of Care
view channel
Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour
Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Smartphone-Enabled, Paper-Based Quantitative Diagnostic Platform Transforms POC Testing
Point-of-care diagnostics are crucial for public health, offering rapid, on-site testing that enables prompt diagnosis and treatment. This is especially valuable in remote or underserved regions where... Read moreBusiness
view channel
Becton Dickinson to Spin Out Biosciences and Diagnostic Solutions Business
Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA), has announced that its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic... Read more